Washington: The US Food and Drug Administration (FDA) has granted an expanded emergency use authorization for Novavax’s COVID-19 vaccine adjuvanted for adolescents aged 12-17 years. The US company said the vaccine is the first protein-based Covid-19 vaccine approved in the US. Doses of Adjuvant are available for use in adolescents at the recommendation of the Centers for Disease Control and Prevention (CDC), the company noted.Also Read – Canada has approved the first COVID booster for children ages 5-11. Check the details here
“Having more vaccine options for use in both adults and adolescents, such as the NovaVax Covid-19 vaccine, adjuvanted will hopefully help increase vaccination rates, especially as we look to the fall onset and back-to-back of Covid-19. Let’s prepare. -School Season,” Stanley C. Erk, president and chief executive officer, Novavax said in a company statement.
Speaking to CNN Sylvia Taylor, Novavax’s senior vice president of global corporate affairs, said, “One of the things that we believe makes our vaccine unique is that we see really good immune responses against the variants with our prototype vaccine. And so, if you think about the vaccines that we’ve already authorized that we’re now talking about being authorized for adolescents, we can actually see a good immune response against the different variants, including Omicron, including BA.1 and BA.5. are.”
In July 2022, the FDA granted emergency use authorization for a two-dose primary series in adults 18 years of age and older, following a recommendation by the CDC Advisory Committee on Immunization Practices and endorsement from the CDC.
(With IANS inputs)
$(".cmntbox").toggle();
);
);
.
Source link
